Aytu Biopharma, Inc 8-K, filed Aug 15, 2023
Aytu Biopharma, Inc (AYTU)
About this 8-K
Aytu Biopharma, Inc filed this 8-K on August 15, 2023, reporting on events of August 11, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
| |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 11, 2023 the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Aytu BioPharma, Inc. (“Aytu” or the “Company”) approved the following bonus for the Named Executive Officers (“NEOs”):
Name |
| Title |
| Bonus Amount |
| % of Target |
|
Joshua R. Disbrow | | Chief Executive Officer | | $118,000 | | 33% | |
Mark K. Oki | | Chief Financial Officer & Secretary | | $ 83,000 | | 50% | |
The bonuses earned by Mr. Disbrow and Mr. Oki will be paid in January 2024. If Mr. Disbrow or Mr. Oki’s employment terminates prior to January 2024, the approved bonus will be paid in full.